## **B.6** Toxicology and metabolism

## MATCHING ACTIVE SUBSTANCE DATA NECESSARY FOR THE RENEWAL OF THE¹ APPROVAL OF ACETAMIPRID

Member State	Month and year	Active Substance <sup>2</sup> (Name)	Notifier
The Netherlands	May 2018	Acetamiprid	Sharda Cropchem Ltd.

 $Active \ substance \ source = Sharda \ CropChem \ Ltd.$ 

## References for the active substance acetamiprid

Data requirement point / reference		pro	dered as relied upon and for w tection has been claimed			submitte	study or case referenced / d by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.1.1/01		1997a	C-NI-25 - Metabolism in Rats Document No. RD-95127 GLP, not published.	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.1.1/02		2003	Metabolism study of Acetamiprid in rat (Determination of IM-1-5), Document No. RD-03028 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	Study or t		dered as relied upon and for w tection has been claimed	hich data	Title o		re study or case referenced / tted by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	study	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.1.1/03		1995	[14C]-NI-25 – Biliary Excretion in Rat Document No. RD-09575 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.1.1/04		1995	Absorption, Distribution, Metabolism, Elimination, and Pharmacokinetics after Chronic Dosing of [ 14C]-NI- 25 in Rat Document No. RD-09576 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.1.1/05		1997Ь	14 <sub>C</sub> -NI-25 - Metabolism Study in Rats (Qualitative and Quantitative Analysis of Metabolites in Group C) Document No. RD 09654N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.1.1/06		1997c	14 <sub>C</sub> -NI-25 - Metabolism in Rats. (A Summary Report). Document No. RD-09785 No GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.2.1/01		1997a	NI-25: Acute Oral Toxicity Study in Rats. Document No. RD-9760 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	Study or to		dered as relied upon and for w tection has been claimed	hich data	Title of		study or case referenced / ed by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	_	Y/N	Submission deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.2.1/02		2002a	Acetamiprid suspended in corn oil: Acute oral toxicity study in rats. Document No RD-II 02425 GLP, not published					5.1 lid 1 c			5.1 lid 1 c
CA 5.2.1/03		1998	Acetamiprid*- Acute oral toxicity study in rats (*Proposed ISO Common Name, Code No.: NI-25. Document No. RD-9528N GPL, Not published	Y	5.1 lid 2 e	2008	Acute oral toxicity of acetamiprid technical in rats. Report No. 7531 Jai research foundation, India GLP, not published	5.1 lid 1 c			5.1 lid 1 c
CA 5.2.2/01		1997ь	NI-25: Acute Dermal Toxicity Study in Rats. Document No. RD-9761 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.2.3/01		1997	Acetamiprid : Acute (four- hour) Inhalation Study in Rats. Document No. RD-09782N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference			dered as relied upon and for w stection has been claimed	hich data	Title of		study or case referenced / ed by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	study	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.2.4/01		1997a	Acetamiprid - Primary Dermal Irritation Study in Rabbits Document No. RD-9533N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.2.5/01		1997Ь	Acetamiprid - Primary Eye Irritation Study in Rabbits Document No. RD-9532N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.2.6/01		1997	Acetamiprid (Code No. : NI- 25) Skin Sensitisation in the Guinea-Pig GLP, not published Document No. RD-09779	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.3.1/01		1992	A 4-Week Oral Toxicity Study of NI-25 in the Dog via Dietary Administration. Document No. RD-09444N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.3.2/01		1997a	Acetamprid - Thirteen Week Dietary Subchronic Toxicity in Rats. Document No. RD-9535N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	•	pro	dered as relied upon and for w tection has been claimed				study or case referenced / ed by applicant	equivalence / justification for non-provision	Cat. 4		RMS Opinion 4.6.7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.3.2/02		1997a	Acetamiprid - Thirteen Week Dietary Subchronic Toxicity Study in Mice Document No. RD-09536N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.3.2/03		1998a	A Sub-chronic (3-month) Oral Toxicity Study of NI-25 in the Dog via Dietary Administration. Document No. RD-09445N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.3.2/04			A Chronic (12-month) Oral Toxicity Study of NI-25 in the Dog via Dietary Administration. Document No. 09446N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.3.2/05	5.1 lid 2 e	2009	In vivo subacute oral acetamiprid toxicity in haematological indices in <i>Rattus norvegicus</i> . Environment and Ecology, Vol 27(4A), pp. 1767-1769	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference			dered as relied upon and for w tection has been claimed				study or case referenced / d by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.3.2/06	5.1 lid 2 e	2012	Studies on the electrolytes and microelements in Wistar rat following multiple exposures to acetamiprid.  Toxicology and Industrial Health, Vol. 28(5), pp. 422-7	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.3.3/01		1997	21-Day Dermal Toxicity Study in Rabbits with Acetamiprid. Document No. RD-09861 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.4.1/ 02	5.1 lid 2 e	1998	Acetamiprid - Reverse Mutation Study on Bacteria Odawara Research Center, Nippon Soda Co. Ltd., Report No. G-0831, Document No. RD-09539N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference			dered as relied upon and for w tection has been claimed	hich data		submitte	study or case referenced / d by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4.6.7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.4.1/03	5.1 lid 2 e	1997b	Acetamiprid - Chromosomal Aberration Study on Chinese Hamster Ovary (CHO) Cells Odawara Research Center, Nippon Soda Co. Ltd., Report No. G-800, Document No. RD- 09540N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.4.1/04	5.1 lid 2 e	1998	Genotoxicity Test on NI-25 in the Assay for Unscheduled DNA Synthesis in Rat Liver Primary Cell Cultures with a Confirmatory Assay Hazleton Washington, Inc. (HWA), Report No. 15901-0- 447R, Document No. RD- 09439N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.4.1/05	5.1 lid 2 e	2012	In vitro genotoxicity evaluation of acetamiprid in CaCo-2 cells using the micronucleus, comet and cH2AX foci assays. Pesticide Biochemistry and Physiology Vol. 104, pp. 212–217.	N				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	·	pro	idered as relied upon and for wotection has been claimed				study or case referenced / ed by applicant	equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.4.2/01		1998	Mutagenicity Test on NI-25 in an <i>in vivo</i> Mouse Micronucleus Assay Document No. RD-9441N2 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.4.2/02		1998	NI-25: Metaphase Analysis in the Rat Bone Marrow <i>in vivo</i> . Document No. RD-09443N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.4.2/03		1997	Unscheduled DNA Synthesis (UDS) Test with Mammalian Liver Cells <i>in vivo</i> Document No. RD-09767N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.5/01		1999	Two-Year Dietary Toxicity and Oncogenicity Study in rats. Document No. RD-99104 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.5/02		1999	18-Month Dietary Oncogenicity Study in Mice. Document No. RD 99103 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	Study or t	pro	dered as relied upon and for w tection has been claimed	hich data	Title of	submitte	study or case referenced / ed by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.6.1/01		1999	Two-Generation reproduction Study with NI-25 in Rats (Reproduction and Fertility Effects). Document No. RD-99102N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.6.2/01		1997a	Acetamiprid - Teratogenicity Study in Rats Document No. RD-09537N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.6.2/02		1997Ь	Acetamiprid - Teratogenicity Study in Rats Document No. RD-09538N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.6.2/03	5.1 lid 2 e	2013	Reproductive effects of two neonicotinoid insecticides on mouse sperm function and early embryonic development <i>In vitro</i> . PLoS one July 2013, Volume 8,	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.6.2/04	5.1 lid 2 e	2013	Oxidative stress: Role in acetamiprid-induced impairment of the male mice reproductive system. Agricultural Sciences in China Vol. 10(5), pp. 786-796	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference			dered as relied upon and for w tection has been claimed	hich data	Title of		study or case referenced / d by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.7.1/01		1997	Acetamiprid Dose Range Finding Neurotoxicity to Rats by Acute Oral Administration (including determination of time to peak effect) Document No. RD-09927 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.7.1/02		1997a	Acetamiprid - Neurotoxicity to Rats by Acute Oral Administration Document No. RD 09928 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.7.1/03		1997ь	Acetamiprid - Neurotoxicity to Rats by Dietary Administration for 13 Weeks Document No. RD-09929 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.7.1/04		2008	An oral developmental neurotoxicity study of acetamiprid in rats Document No.: RD-01310 GLP, Not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	Study or t		dered as relied upon and for w tection has been claimed	hich data	Title of a	alternative submitte	study or case referenced / d by applicant	Reason for equivalence / justification for non-provision	Cat. 4 (		RMS Opinion 4.6.7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.7.1/05		2006	Rebuttal of Data Evaluation Record for Acetamiprid (WIL No. 21193, EPA Acetamiprid 099050, MRID 46255619) Document No. RD-00952 Not GLP, Not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.7.1/06	5.1 lid 2 e	2007 a	Characterization of Critical Toxicology Endpoints for Acetamiprid Risk Assessment: Auditory Startle Habituation and Maternal Toxicity from the Developmental Neurotoxicology Study (MRID 47191101) Exponent, USA, dated April 6, 2007. Document No. RD-02833 Not GLP, Not published					5.1 lid 1 c			5.1 lid 1 c
CA 5.7.1/07	5.1 lid 2 e	2007	Acetamiprid DNT Study (WIL- 21193): Statistical analysis for auditory startle response. DP Barcode 341525 CEB memo dated July 24, 2007 Not GLP, Published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference			dered as relied upon and for w tection has been claimed	hich data	Title of		study or case referenced / ed by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	study	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.7.1/08	5.1 lid 2 e	2007 b	Acetamiprid DNT Study (WIL- 21193; MRID 46255619): Response to EPA CEB Statistical Analyses and Weight of Evidence Supporting NOAEL of 10 mg/kg bwt/day Exponent, Inc., USA, Report dated September 17, 2007, Document No. RD- 02486 Not GLP, Not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.7.1/09	5.1 lid 2 e	2008	Acetamiprid: Data evaluation record for Acetamiprid developmental neurotoxicity study and EPA response to rebuttals submitted by Nisso America. PC Code 099050 Not GLP, Published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.7.1/ 10	5.1 lid 2 e	2013	EFSA PPR Panel (EFSA Panel on Plant Protection Products and their Residues), 2013. Scientific Opinion on the developmental neurotoxicity potential of acetamiprid and imidacloprid. EFSA Journal 2013;11(12):3471. [51 pp.] doi:10.2903/j.efsa.2013.3471. Not GLP, Published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference			lered as relied upon and for w tection has been claimed			submitte	study or case referenced / d by applicant	equivalence / justification for non-provision	Cat. 4		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.7.1/11	5.1 lid 2 e	2014a	Response to EFSA PPR Scientific Opinion on the Acetamiprid DNT Study Exponent, USA, Doc. no. 1400668.000 – 2130, dated March 2014 Document No. RD-02799 Not GLP, Not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.7.1/12	5.1 lid 2 e	2014b	Addendum to Response to EFSA PPR Scientific Opinion on the Acetamiprid DNT Study Previously Submitted March 2014 2014 – Information requested by EFSA and new analysis.  Exponent, USA, Doc. no. 1400668.000 – 6351, dated July 10 2014. Document No. RD-02892 Not GLP, Not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.7.1/13	5.1 lid 2 e	2015	EFSA PPR Panel 2015. Response of EFSA PPR Panel to the Nippon Soda Co., Ltd. Report on the potential DNT of acetamiprid.	N				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	Study or to	est consid pro	lered as relied upon and for w tection has been claimed				study or case referenced / ed by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion <sup>4,6,7</sup> a) GLP- compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	Submission deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.7.2/01		1997	NI-25 Acute Delayed Neurotoxicity Study in the Domestic Hen Nippon-Soda Report No.: RD- 9438N GLP Not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/01	-	1997c	IM-0 - Acute Oral Toxicity Study In Rats. Document No. RD-9585N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/02		1997c	IM-0 - Thirteen Week Dietary Subchronic Toxicity Study in Rats. Document No. RD-97108 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	Study or to		lered as relied upon and for w ection has been claimed	hich data	Title of a		study or case referenced / ed by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion <sup>4,6,7</sup> a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.8.1/03	-	1997a	IM-0 - Reverse Mutation Study on Bacteria Document No. RD-09586N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/04	-	1997d	IM-1-2 - Acute Oral Toxicity Study In Rats. Document No. RD-95133N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/05	5.1 lid 2 e	1997b	IM-1-2 - Reverse Mutation Study on Bacteria Nippon Soda Co. Odawara Research Center Japan, Report No. G-964, Document No. RD-9601N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/06	-	1997e	IM-1-3: Acute Oral Toxicity Study In Rats. Document No. RD-95142N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference			lered as relied upon and for w ection has been claimed	hich data	Title of a		study or case referenced / d by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion <sup>4,6,7</sup> a) GLP- compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.8.1/07	5.1 lid 2 e	1997c	IM-1-3 - Reverse Mutation Study on Bacteria Odawara Research Center, Nippon Soda Co. Ltd., Report No. G-936, Document No. RD-95143N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/08	-	1998a	IM-1-4 - Acute Oral Toxicity Study In Rats. Document No. RD-9828N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c.
CA 5.8.1/09	-	1998b	IM-1-4 - Acute Oral Toxicity Study In Rats. Document No. RD-9829N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/10	-	1999	13-Week Dietary Subchronic Toxicity Study with IM-1-4 in Rats. Document No. RD-9903 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	quirement protection has been claimed point / eference				Title of	alternative submitte	study or case referenced / ed by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion 4.6.7  a) GLP- compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	study	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	•	Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.8.1/11	5.1 lid 2 e	1997d	IM-1-4 - Reverse Mutation Study on Bacteria. Odawara Research Center, Nippon Soda Co. Ltd., Report No. G-940, Document No. RD-09602N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/12	-	1998	Mutagenicity test on IM-1-4 in the CHO/HGPRT forward mutation assay. Covance Laboratories Inc., Report No. 6840-106, 18981- 0-435, Document No. RD-9834 GLP, not published	N	5.1 lid 2 e		Study Plan Kadam, SB. [6-chloropyridin-3-yl) methyl] (methyl) amine (Acetamiprid Metabolite IM-1-4) Study No. P/17784/CGMT/18 Intox Pvt. Ltd., India GLP, not published	5.1 lid 1 c	Y	8 months	5.1 lid 1 c
CA 5.8.1/13	-	1998	Mutagenicity Test on IM-1-4 in the <i>in vivo</i> Mouse Micronucleus Assay Document No. RD-9835 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/14	-	1997	IM-1-5*HCl: Acute oral toxicity study in rats. Document No. RD-97109 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference		pro	dered as relied upon and for watertion has been claimed			submitte	study or case referenced / d by applicant	equivalence / justification for non-provision	Cat. 4		RMS Opinion 4.6.7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	study	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.8.1/15	-	2002b	IM-1-5: Acute oral toxicity study in rats. Document No. RD-II 02424 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/16	5.1 lid 2 e	1997с	IM-1-5 - reverse mutation study on bacteria. Odawara Research Center, Nippon Soda Co. Ltd., Report No. H145, Document No. RD-97101 GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	Study or to		lered as relied upon and for w tection has been claimed	hich data	Title of		study or case referenced / ed by applicant	equivalence / justification for non-provision		data <sup>5</sup>	RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.8.1/17	5.1 lid 2 e	2012a	IM-1-5: Bacterial Reverse Mutation Test in Salmonella typhimurium TA 1535, TA 100, TA 1537 and TA 98 and Escherichia coli WP2uvrA (OECD 471) Charles River, UK, Report No. 32827, Document No. RD- 02354 GLP, not published		5.1 lid 2 e	2019	Study plan Kamarkar, AA. N-[6-chloropyridin-3-yl) methyl]-N-methyl ethanimidamide hydrochloride (Acetamiprid IM-1-5) Study No. P/17785/AMES/18 Intox Pvt. Ltd., India GLP, not published  Soman Y.A N-[6-chloropyridin-3-yl) methyl]-N-methyl ethanimidamide hydrochloride (Acetamiprid IM-1-5)	5.1 lid 1 c	Y	8 months	5.1 lid 1 c
							Salmonella typhimurium Reverse Mutation Assay Study No. R/17785/AMES/19 Intox Pvt. Ltd., India GLP, not published				

Data requirement point / reference	Study or to	lered as relied upon and for w ection has been claimed	hich data	Title of alternative study or case referenced / submitted by applicant  eAuthor(s) Year Title			Reason for equivalence / justification for non-provision	Cat. 4 o		RMS Opinion <sup>4,6,7</sup> a) GLP-compliant?
number	Author(s)	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)		Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
					2019					

Data requirement point / reference	Study or to		ered as relied upon and for w ection has been claimed	hich data	Title of		study or case referenced / d by applicant	Reason for equivalence / justification for non-provision	Cat. 4		RMS Opinion <sup>4,6,7</sup> a) GLP- compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	•	Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.8.1/18	5.1 lid 2 e	2012b	IM-1-5: In vitro Mammalian Cell Gene Mutation Test in Mouse Lymphoma L5178Y Cells (OECD 476) Charles River, UK, report No. 32830, Document No. RD- 02372 Nippon-Soda Report No.: RD- 02372 GLP, not published		5.1 lid 2 e		Study plan Kadam, SB. N-[6-chloropyridin-3-yl) methyl]-N-methyl ethanimidamide hydrochloride (Acetamiprid IM-1-5) Study No. P/17786/CGMT/18 Intox Pvt. Ltd., India GLP, not published	5.1 lid 1 c	Y	8 months	5.1 lid 1 c
CA 5.8.1/19			IM-2-1 - Acute Oral Toxicity Study In Rats. Document No. RD-95135N GLP, not published Nippon-Soda Report No.: RD- 02372 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	Study or to	lered as relied upon and for w tection has been claimed	hich data	Title of a		study or case referenced / ed by applicant	Reason for equivalence / justification for non-provision		RMS Opinion 4,6,7 a) GLP-compliant?
number	Author(s)	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.8.1/20	5.1 lid 2 e	IM-2-1 - Reverse Mutation Study on Bacteria Odawara Research Center, Nippon Soda Co. Ltd., Report No. G-932, Document No. RD-9587N GLP, not published	N				5.1 lid 1 c		5.1 lid 1 c
CA 5.8.1/21		IM-2-3: Acute Oral Toxicity Study In Rats. Document No. RD-95144N GLP, not published	Y				5.1 lid 1 c		5.1 lid 1 c
CA 5.8.1/22	5.1 lid 2 e	IM-2-3 - Reverse Mutation Study on Bacteria Odawara Research Center, Nippon Soda Co. Ltd., Report No. G-938, Document No. RD-09603N GLP, not published	N				5.1 lid 1 c		5.1 lid 1 c
CA 5.8.1/23		IS-1-1: Acute Oral Toxicity Study In Rats. Document No. RD-95140N GLP, not published	Y				5.1 lid 1 c		5.1 lid 1 c

Data requirement point / reference			lered as relied upon and for w tection has been claimed	hich data	Title of a		study or case referenced / ed by applicant	Reason for equivalence / justification for non-provision	Cat. 4 (		RMS Opinion <sup>4,6,7</sup> a) GLP-compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.8.1/24	5.1 lid 2 e	1997g	IS-1-1 - Reverse Mutation Study on Bacteria Odawara Research Center, Nippon Soda Co. Ltd., Report No. G-948, Document No. RD-09606N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/25		1997i	IS-2-1: Acute Oral Toxicity Study In Rats Document No. RD-95141N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/26	5.1 lid 2 e	1997h	IS-2-1 - Reverse Mutation Study on Bacteria Odawara Research Center, Nippon Soda Co. Ltd., Report No. G-946, Document No. RD-9607N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.1/27		1997j	IC-0 - Acute Oral Toxicity Study In Rats. Document No. RD-95137N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference	,	prot	dered as relied upon and for w tection has been claimed			submitte	study or case referenced / d by applicant	equivalence / justification for non-provision	equivalence / justification for non-provision			
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?	
CA 5.8.1/28	5.1 lid 2 e	1997i	IC-0 - Reverse Mutation Study on Bacteria Odawara Research Center, Nippon Soda Co. Ltd., Report No. G-942, Document No. RD-09605N GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c	
CA 5.8.1/29	-	1999z	IB-1-1: Acute Oral Toxicity in Rats Document No. RD-9906 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c	
CA 5.8.1/30	5.1 lid 2 e	1997j	IB-1-1: Reverse Mutation Study on Bacteria. Odawara Research Center, Nippon Soda Co. Ltd., Report No. H163, Document No. RD-9915 GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c	
CA 5.8.2/01		2010	Acetamiprid: 4-Week Dietary Immunotoxicity Study in the Rat. Document No. RD-02011 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c	

Data requirement point / reference			dered as relied upon and for w tection has been claimed	hich data	Title of		study or case referenced / d by applicant	Reason for equivalence / justification for non-provision	quivalence / stification for on-provision		
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.8.2/02		2010	4-Week Acetamiprid: Dietary Immunotoxicity studies in mouse. Document No. RD-02019 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.2/03	-	1997	Acetamiprid: Pharmacological Studies in Experimental Animals. Document No. RD-09578N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.8.2/04	5.1 lid 2 e	2012	Nephrotoxicity of acetamiprid on male mice and the rescue role of Vitamin E. Journal of Animal and Veterinary Advances Vol. 11(15), pp. 2721- 2726	Y				5.1 lid 1 c			5.1 lid 1 c
CA 5.9.1/01	5.1 lid 2 e	2014	Human Handling Experiences From Plant Employees Manufacturing Acetamiprid (No. 3) Nippon Soda Co., Ltd, Document No. RD-02879 Non-GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference			lered as relied upon and for w ection has been claimed	hich data	Title of		study or case referenced / d by applicant	equivalence / justification for non-provision	Cat. 4		RMS Opinion <sup>4,6,7</sup> a) GLP- compliant?
number	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	study	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	deadline	b) Guideline- compliant? c) Equivalent endpoint?
CA 5.9.1/02	5.1 lid 2 e	2007	Human Handling Experiences From Plant Employees Manufacturing Acetamiprid (No. 2). Nippon Soda Co., Ltd, Document No. RD-01239 Non-GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.9.1/03	5.1 lid 2 e	1998	Human Handling Experiences From Plant Employees Manufacturing Acetamiprid Nippon Soda Co., Ltd, , Document No. RD-9849 Non-GLP, not published	N				5.1 lid 1 c			5.1 lid 1 c
CA 5.9.6/01			Acetamiprid: Detoxification Studies for Acute Toxicity of NI- 25 Document No. RD-95108N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

## References for the PPP Acetamiprid 20 SC

Data requirement point / reference number	Study or t		idered as relied upon and for wotection has been claimed	hich data	Title of		e study or case referenced / ted by applicant	Reason for equivalence / justification for		data <sup>5</sup>	a) GLP- compliant? b) Guideline- compliant? c) Equivalent endpoint?
	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	non-provision	Y/N	Submission deadline	
KCP 7.1.1/1		1998	Acute Oral Toxicity in Rats - EXP 60707B Document No. RD-9943 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
KCP 7.1.2/1		1998	Acute Dermal Toxicity in Rats - EXP 60707B Document No. RD-9944 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
KCP 7.1.3/1		1999	Acetamiprid 20% SP - Acute Inhalation Toxicity Study in Rats Document No.RD-9545N GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
KCP 7.1.4/1		1998	Acute Dermal Irritation in Rabbits - EXP 60707B Document No. RD-9945 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
KCP 7.1.5/1		1998	Acute Eye Irritation in Rabbits - EXP 60707B Document No. RD-9946 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c

Data requirement point / reference number	Study or t		dered as relied upon and for w tection has been claimed	hich data	Title of		e study or case referenced / ted by applicant	Reason for equivalence / justification for	Cat. 4	data <sup>5</sup>	RMS Opinion 4,6,
	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not	Vertebrate study Y/N	Author(s)	Year	Title Company Report No. Source (where different from company) GLP or GEP status Published or not		Y/N	Submission deadline	compliant? b) Guideline- compliant? c) Equivalent endpoint?
KCP 7.1.6/1		1998	Skin Senzitisation Test in Guinea Pig. EXP 60707B. Document No. RD-9947 GLP, not published	Y				5.1 lid 1 c			5.1 lid 1 c
KCP 7.3/01	5.1 lid 2 e	2014	The In Vitro Percutaneous Absorption of Radiolabelled Acetamiprid in the Concentrate and One In- Use Spray Dilution of Acetamiprid 20SP Through Human Skin Charles River, UK, Report No. 34871, Document No. RD- 02802 GLP, Not published				Study plan In vitro percutaneous absorption of Acetamiprid, formulated as Acetamiprid 20% SG, through human skin. Study No.: P21130/26 Triskelion B.V., The Netherlands GLP, not published	5.1 lid 1 c	Y	8 months	5.1 lid 1 c
					5.1 lid 2 e	2019	In vitro percutaneous absorption of Acetamiprid, formulated as Acetamiprid 20 % SG, through human skin Triskelion Report No. V21130/26 GLP: Yes Unpublished	5.1 lid 1 c			5.1 lid 1 c